Abstract
This chapter of New Drug Futures evaluates, compares and contrasts the
prospects for the compounds that will revolutionise the pharmaceutical
industry over the next 5 years and beyond in the vaccines sector. The report
includes unique sales forecasts by major product.
The full 400-page report, evaluates, compares and contrasts the prospects for
the compounds that will revolutionise the pharmaceutical industry over the
next 5 years and beyond. The report covers 8 key therapy areas
(alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS,
musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by
major product. Click here for more information. This chapter is available
separately.
We estimate that vaccines generated sales of over US$10.6 billion in 2005,
with over 50% derived from traditional, domestic paediatric vaccines and the
development of novel vaccines that can command price premiums.
The market is beginning to turn around after a period of slow growth and it is
forecast to be worth nearly US$20 billion by 2010. Growth will be driven
principally by the adolescent and adult vaccine segment of the market as well
as the development of therapeutic vaccines.
The market has attracted the attention of eleven pharma players, with six of
these accounting for around 90% of vaccine sales by value.
View Cart
